TenX Keane shareholders approve merger with Citius subsidiary

TenX Keane Acquisition (TENK) announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly owned oncology subsidiary of Citius Pharmaceuticals (CTXR).The newly combined public company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology. The transaction has been unanimously approved by the Board of Directors of TenX, Citius Pharma, and Citius Pharma’s oncology subsidiary. Subject to certain contractual as well as customary closing conditions, the merger is expected to be completed in the coming weeks. The transaction is expected to provide Citius Oncology with improved access to the public equity markets, support the commercialization of LYMPHIR, if approved, and position the company to explore additional targeted oncology opportunities.